Improve Medical Instruments Co AAQS
The The AAQS of Improve Medical Instruments Co (300030.SZ) as of Nov 18, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
1
YoY
0.00%
Last updated:
Improve Medical Instruments Co has a current AAQS of 1.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Improve Medical Instruments Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Improve Medical Instruments Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The Improve Medical Instruments Co AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2018
1.00 CNY
Jan 1, 2019
1.00 CNY
Jan 1, 2020
1.00 CNY
Jan 1, 2021
1.00 CNY
Jan 1, 2022
1.00 CNY
Jan 1, 2023
1.00 CNY
Jan 1, 2024
1.00 CNY
Jan 1, 2025
1.00 CNY
| YEAR | AAQS | YoY |
|---|---|---|
| 1 | 0.00% | |
| 1 | 0.00% | |
| 1 | 0.00% | |
| 1 | 0.00% | |
| 1 | 0.00% | |
| 1 | 0.00% | |
| 1 | 0.00% | |
| 1 | 0.00% | |
| 1 | 0.00% | |
| 1 | 0.00% | |
| 1 | 0.00% | |
| 1 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Improve Medical Instruments Co Stock analysis
What does Improve Medical Instruments Co do? Improve Medical Instruments Co., Ltd. generates revenue through clinical care services, testing laboratory operations, and financial leasing of medical equipment. The company sells vacuum blood collection systems, liquid biopsy tubes, automatic blood collection tube detachers, thromboelastometers, reagents, hospital intelligent blood collection management systems, and sub-medical record systems (EMR). Its products are exported to Russia, Saudi Arabia, Brazil, and South Korea, with additional offerings including masks, instruments, and reagents. The firm serves healthcare providers and medical facilities globally through these product lines and services.
The company's revenue streams include the sale of medical equipment and related products, as well as financial leasing services for medical devices. Products like vacuum blood collection systems and hospital management systems target hospitals and laboratories, while exports to countries such as Russia and Brazil indicate a focus on international markets. The firm's product portfolio spans diagnostic tools, blood collection solutions, and EMR systems, catering to diverse healthcare needs.
Improve Medical Instruments Co., Ltd. provides clinical care and testing laboratory services alongside product sales, with a strong emphasis on exporting medical equipment and reagents. The firm's export markets include Russia, Saudi Arabia, Brazil, and South Korea, where its vacuum blood collection systems, thromboelastometers, and EMR systems are in demand. Revenue is derived from both direct product sales and financial leasing of medical equipment to healthcare institutions. Improve Medical Instruments Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Improve Medical Instruments Co stock
The AAQS of Improve Medical Instruments Co is 1 in 2025.
On Eulerpool you can find the complete historical development of The AAQS Improve Medical Instruments Co since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Improve Medical Instruments Co
All Key Metrics — Improve Medical Instruments Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth